The cocrystal approach has been extensively investigated over the last decade as one of the most promising methods toward modifying the dissolution behavior of insoluble drug substances. This study demonstrates that the polymorphism of pharmaceutical cocrystalline powders prepared via antisolvent methods can be controlled using kinetic parameters. A carbamazepine-saccharin (CBZ-SAC) cocrystal was selected as a model drug in this study. This crystal was manufactured through a scaled-up antisolvent process with a total solution volume of 4.5 L. CBZ-SAC cocrystal crystalline powders were synthesized by adding 3 L of water as the antisolvent into 1.5 L of CBZ and SAC in methanol, whereby the antisolvent addition rate and the agitation speed were varied as the principal kinetic parameters. To investigate how cocrystallization proceeds under each condition, periodical sampling was combined with off-line characterization_x000D_ and in-line near-infrared (NIR) measurements to monitor the progress of reaction over the 120-minute process. We found that the creation of form-I was preferred when the addition speed or agitation speed was increased, but a highly pure form-II resulted if kinetic conditions were reversed. These differences in polymorphism can be explained by changes in kinetic characteristics when the process is monitored by NIR. This study is directly applicable to the_x000D_ industrial synthesis of these types of materials, precisely when specific CBZ-SAC cocrystalline polymorphs must be manufactured on a large scale.

Co-crystal Carbamazepine Anti-solvent Scale-up Near-infrared In-line Monitoring Kinetic Parameter

FDA, Guidance for industry; Regulatory classification of pharmaceutical co-crystals, http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm (2013).
Babu NJ, Nanjia A, Cryst. Growth Des., 11, 2662 (2011)
Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G, Int. J. Pharm., 419, 1 (2011)
Brittain HG, J. Pharm. Sci., 102, 311 (2013)
Steed JW, Trends Pharmacol. Sci., 34, 185 (2013)
Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodriguez-Hornedo N, Int. J. Pharm., 453, 101 (2013)
Padrela L, Rodrigues MA, Velaga SP, Matos HA, deAzevedo EG, Eur. J. Pharm. Sci., 38, 9 (2009)
ter Horst JH, Cains PW, Cryst. Growth Des., 8, 2537 (2008)
Dhumal RS, Biradar SV, Paradkar AR, York P, Int. J. Pharm., 368, 129 (2009)
Alhalaweh A, Velaga SP, Cryst. Growth Des., 10, 3302 (2010)
ter Horst JH, Deij MA, Cains PW, Cryst. Growth Des., 9, 1531 (2009)
Yamamoto K, Tsutsumi S, Ikeda Y, Int. J. Pharm., 437, 162 (2012)
Bag PP, Patni M, Reddy CM, CrystEngComm, 13, 5650 (2011)
Porter WW III, Elie SC, Matzger AJ, Cryst. Growth Des., 8, 14 (2008)
Wu TK, Lin SY, Lin HL, Huang YT, Bioorg. Med. Chem. Lett., 21, 3148 (2011)
Good DJ, Rodriguez-Hornedo N, Cryst. Growth Des., 9, 2252 (2009)
Buanz ABM, Parkinson GN, Gaisford S, Cryst. Growth Des., 11, 1177 (2011)
Limwikrant W, Nagai A, Hagiwara Y, Higashi K, Yamamoto K, Moribe K, Int. J. Pharm., 431, 237 (2012)
Rager T, Hilfiker R, Cryst. Growth Des., 10, 3237 (2010)
Profio GD, Grosso V, Caridi A, Caliandro R, Guagliardi A, Chita G, Curcio E, Drioli E, CrystEngComm, 13, 5670 (2011)
Caridi A, Di Profio G, Caliandro R, Guagliardi A, Curcio E, Drioli E, Cryst. Growth Des., 12, 4349 (2012)
Sheikh AY, Rahim SA, Hammond RB, Roberts KJ, CrystEngComm, 11, 501 (2009)
Wang IC, Lee MJ, Sim SJ, Kim WS, Chun NH, Choi GJ, Int. J. Pharm., 450, 311 (2013)
Lee MJ, Chun NH, Wang IC, Liu JJ, Jeong MY, Choi GJ, Cryst. Growth Des., 13, 2067 (2013)
Chun NH, Wang IC, Lee MJ, Jung YT, Lee SK, Kim WS, Choi GJ, Eur. J. Pharm. Biopharm., 85, 854 (2013)
Pagire SK, Korde SA, Whiteside BR, Kendrick J, Paradkar A, Cryst. Growth Des., 13, 4162 (2013)
Lu E, Rodriguez-Hornedo N, Suryanarayanan R, CrystEngComm, 10, 665 (2008)